CHICAGO (GenomeWeb) – Pharmacogenomic informatics company OneOme has been chosen to interpret and package data for the Right 10K study, a collaboration between Mayo Clinic and the Baylor College of Medicine, the Minneapolis-based company said.
Right 10K is an effort to sequence 76 pharmacogenes from Mayo Clinic Biobank samples of 10,000 Mayo patients in order to assess the ability of PGx testing to improve long-term health.
The vendor will provide each patient with a OneOme RightMed PGx interpretation report through an integration with Mayo's Epic Systems electronic medical records. All 10,000 participants receive all of their care at the flagship Mayo campus in Rochester, Minnesota, according to the Right 10K website. Baylor conducts the genomic sequencing.
Founded in late 2013 as a joint venture of Mayo Clinic and early-stage venture firm Invenshure, OneOme had been focused exclusively until mid-2016 on PGx interpretation services for patients at Mayo.